FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma

The FDA has approved an iberdomide-based therapy as a new treatment option for patients with relapsed/refractory multiple myeloma, providing an alternative approach for this challenging hematologic cancer.

This Wire brief sits within Fusion42's coverage of Biotech.